Davita Inc vs Genuine Parts Company — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while Genuine Parts Company trades at $126.99 (market cap $17.67B). The key difference: Genuine Parts Company is the larger of the two by market cap, and Genuine Parts Company pays a 3.32% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Genuine Parts Company for 75 Days on average.
| DVA | GPC | |
|---|---|---|
Market Cap | $11.29B | $17.67B |
Volume | 582,204 | 1,079,458 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $149.26 |
52-Week Low | $103.87 | $92.47 |
Typical Hold Time | 114 Days | 75 Days |
Enterprise Value | $24.01B | $23.76B |
Dividend Yield | — | 3.32% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
GPC trades at $127.16, up 1.4% today, near its pivot point of $127 with technical indicators showing a bullish trend. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 2026 results due October 20. Revenue growth is steady, but net income margins have compressed significantly to 0.13% in 2025. Analysts maintain a consensus price target of $145.75, with 43% recommending Buy. Key developments include the planned spinoff of its industrial unit, Motion, scheduled for Q1 2027.
The outlook for GPC is cautiously optimistic, driven by the potential value unlock from the corporate split and its position in the resilient automotive aftermarket. However, thin profit margins and rising debt levels pose risks. The stock offers a dividend yield supported by its Dividend King status, but investors should weigh execution risks around the separation against the prospect of segment-specific reratings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →